<DOC>
	<DOCNO>NCT01969578</DOCNO>
	<brief_summary>Salivary Gland ( SG ) Cancers rare heterogeneous group tumor , usually approach multidisciplinary team high specialized center . Until today standard care exist treat cancer . The identification target , androgen receptor , SG tumor allow new treatment strategy option rare group disease . As matter fact , strong positivity androgen expression find salivary duct carcinoma adenocarcinoma . The purpose study therefore evaluate efficacy safety chemotherapy versus androgen deprivation therapy ( ADT ) patient recurrent and/or metastatic AR express SGCs . The study include two cohort patient : Cohort A , comprise chemo-naïve patient , Cohort B , comprise pretreated patient .</brief_summary>
	<brief_title>Androgen Deprivation Therapy Advanced Salivary Gland Cancer</brief_title>
	<detailed_description>Patients Cohort A randomize 1:1 study entry receive ADT ( triptorelin + bicalutamide 50 mg ) standard chemotherapy . Patients Cohort A randomized control arm ( chemotherapy arm ) give option enter Cohort B time disease progression . As long Cohort A open recruitment , patient treat chemotherapy simultaneously enrol Cohort B . Accrual Cohort B stop recruitment 76 eligible patient Cohort A reach .</detailed_description>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<criteria>Histologically proven diagnosis recurrent and/or metastatic salivary duct cancer ; adenocarcinoma , NOS ; AR expression least 70 % nuclei neoplastic cell base central review Sufficient tissue must available either historically biopsy must do part study send central review patient enrol cohort Presence least one unidimensional measurable lesion CTscan MRI accord RECIST criterion version 1.1 ( target lesion ) . Patients older 18 year old ; Performance Status ECOG 01 ; Adequate bone marrow function : WBC ≥ 3.5/10exp9L absolute neutrophil count ≥ 1,5x10exp9/L hemoglobin &gt; 9 g/dL platelet count ≥ 100x10exp9/L Adequate liver function : AST &lt; 2.5 time upper limit normal ALT &lt; 2.5 time upper limit normal bilirubin &lt; 1.5 time upper limit normal concomitant evidence AST &lt; 2.5 time upper limit normal , ALT &lt; 2.5 time upper limit normal bilirubin &gt; 1.5 time upper limit normal allow Adequate renal function : serum creatinine level ( ≤ 1.3 mg/dL ) calculate creatinine clearance ≥ 60 mL/min base standard Cockcroft Gault formula Adequate cardiac function demonstrate clinically normal 12 lead ECG ; additionally patient receive Cisplatin Doxorubicin adequate cardiac function demonstrate leave ventricular ejection fraction ( LVEF ) ≥ 50 % ( within 2 week prior treatment start ) Actively bleed tumor patient intend treated carboplatin Patients bone disease brain disease sole disease site ; brain metastasis allow case systemic disease , must treat least 4 week enrollment must stable ; recent history congestive heart failure , unstable angina within past 3 month , cardiac arrhythmia , myocardial infarction , congenital long QTc prolongation , stroke , TIA within past 6 month ; previous cardiac toxicity induce another anthracycline previous exposure maximum cumulative dose another anthracycline patient intend treated doxorubicin history allergic reaction attribute compound similar chemical biological composition cis/carboplatin , paclitaxel , doxorubicin , bicalutamide triptorelin ; concomitant medication terfenadine , astemizole , cisaprid use phenytoin Patients receive vaccine yellow fever active second malignancy last five year except non melanomatous skin cancer carcinoma situ cervix ; positive serum pregnancy test within 1 week prior first dose study treatment Women child bear potential ( WOCBP ) ; adequate birth control measure , define investigator , study treatment period least 6 month last study treatment patient childbearing / reproductive potential . psychological , familiar , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial ; write informed consent give accord ICH/GCP , national/local regulation , patient registration participation another interventional clinical trial precede 4 week prior randomization cohort A patient : previous chemotherapy recurrent/metastatic disease ( previous chemotherapy give concomitantly RT past allow , include cisplatin complete least 6 month enrollment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>salivary duct cancer</keyword>
	<keyword>adenocarcinoma , NOS</keyword>
	<keyword>androgen deprivation</keyword>
	<keyword>androgen receptor</keyword>
</DOC>